AleAnna (NASDAQ:ANNA – Get Free Report) and Xeris Biopharma (NASDAQ:XERS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Institutional & Insider Ownership
38.1% of AleAnna shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 42.9% of AleAnna shares are held by company insiders. Comparatively, 6.5% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares AleAnna and Xeris Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AleAnna | -46.01% | -14.90% | -8.74% |
| Xeris Biopharma | 0.19% | -5.33% | 0.16% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AleAnna | $16.67 million | 15.35 | -$12.34 million | $0.04 | 96.00 |
| Xeris Biopharma | $291.85 million | 3.57 | -$54.84 million | ($0.01) | -604.00 |
AleAnna has higher earnings, but lower revenue than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
AleAnna has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for AleAnna and Xeris Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
| Xeris Biopharma | 1 | 2 | 5 | 0 | 2.50 |
Xeris Biopharma has a consensus price target of $10.08, suggesting a potential upside of 66.94%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than AleAnna.
Summary
Xeris Biopharma beats AleAnna on 9 of the 14 factors compared between the two stocks.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Receive News & Ratings for AleAnna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AleAnna and related companies with MarketBeat.com's FREE daily email newsletter.
